The Attitudes and Beliefs of Oncology Nurse Practitioners Regarding Direct-to-Consumer Advertising of Prescription Medications
Purpose/Objectives: To obtain information about the knowledge and attitudes of oncology nurse practitioners (ONPs) concerning the effect of direct-to-consumer (DTC) advertising of prescription medications on prescribing patterns.
Design: Exploratory survey.
Setting: Oncology Nursing Society Nurse Practitioner Special Interest Group members in the United States.
Sample: 221 of 376 ONPs completed the survey (58%).
Methods: Researcher-developed 12-question postal survey.
Main Research Variables: Knowledge and attitudes of ONPs on DTC advertising effects on prescribing patterns.
Findings: The findings were similar to those of previous studies of physicians regarding the number of visits when patients requested DTC-advertised medications. Major differences were the positive attitudes of ONPs toward potentially longer patient visits to explain and educate patients regarding medication requests based on DTC advertising and smaller percentages of ONPs who felt "pressured" to prescribe requested medications.
Conclusions: ONPs have mixed opinions regarding the practice of DTC advertising but do not believe that they are influenced heavily by advertising with regard to prescriptive practices. ONPs consider patient encounters for education purposes as appropriate and include information about requested DTC-advertised medications in their approach to patient care.
Implications for Nursing: This is an exploratory survey of a specialty group of ONPs. More research is needed to further explore the practice of DTC advertising and potential influences on the prescribing patterns of ONPs. DTC advertising of prescription medications is increasing; ONPs need to increase their knowledge base about the potential for influences of prescriptive practices.
Jump to a section
References
Aiken, K.J., & Swasy, J.L. (2003). Direct-to-consumer advertising of prescription drugs: Selected patient and physician survey findings. Retrieved October 2, 2003, from http://www.fdli.org/conf/handouts/advertising/aiken.pdf
Bell, R.A., Wilkes, M.S., & Kravitz, R.L. (1999). Advertisement-induced prescription drug requests: Patients' anticipated reactions to a physician who refuses. Journal of Family Practice, 48, 446-452.
Berger, J.T., Kark, P., Rosner, F., Packer, S., & Bennett, A.J. (2001). Direct-to-consumer drug marketing: Public service or disservice? Mount Sinai Journal of Medicine, 68, 197-202.
Cornell, S. (1999). Direct-to-consumer drug advertising: Information, persuasion, or both? ADVANCE for Nurse Practitioners, 7(9), 65-66, 82.
Elliot, V.S. (2001). Questions swirl around drug ads for patients. Retrieved September 29, 2003, from www.amednews.com/2001/hll10709
Findlay, S.D. (2001). Direct-to-consumer promotion of prescription drugs: Economic implications for patients, payers, and providers. Pharmaco-ecomonics, 19, 109-119.
Fischer, L. (2003). Advertising for prescription drugs: Dangerous to your health? Retrieved November 24, 2003, from http://advancement.uark.edu/news/NEWS_ARCHIVES/JUN03/cho.html
Gray, S., & Olopade, O.I. (2003). Direct-to-consumer marketing of genetic tests for cancer: Buyer beware [Editorial]. Journal of Clinical Oncology, 21, 3191-3193.
Hannigan, J.E. (2003). Direct drug advertising to consumers: When pharma plays doctor [Letter to the editor]. Journal of Clinical Oncology, 21, 3375.
Henney, J.E. (2000). Challenges in regulating direct-to-consumer advertising. MSJAMA Online. Retrieved September 30, 2003, from http://jama.amaassn.org/cgi/content/full/284/17/2242
Holmer, A.F. (1999). Direct-to-consumer prescription drug advertising builds bridges between patients and physicians. JAMA, 281, 380-382.
Huang, A.J. (2000). The rise of direct-to-consumer advertising of prescription drugs in the United States. JAMA, 284, 2240.
Ives, N. (2003, September 29). FDA ponders pros and cons of the ways prescription drugs are promoted to consumers. The New York Times, C11.
Kaiser Family Foundation. (2001). Prescription drug trends: A chartbook update. Retrieved November 24, 2003, from http://www.kff.org/rxdrugs/3057-03-index.cfm
Kravitz, R.L. (2000a). Direct-to-consumer advertising of prescription drugs. Western Journal of Medicine, 173, 221-222.
Kravitz, R.L. (2000b). Direct-to-consumer advertising of prescription drugs: Implications for the patient-physician relationship. JAMA, 284, 2244.
Lipsky, M.S., & Taylor, C.A. (1997). The opinions and experiences of family physicians regarding direct-to-consumer advertising. Journal of Family Practice, 45, 495-499.
Mail Research Center. (2004). The importance of high response rates. Retrieved April 21, 2004, from http://www.b2bmrc.com/responserate.htm
Mechanic, D. (2003). Physician discontent: Challenges and opportunities. JAMA, 290, 941-946.
Mello, M.M., Rosenthal, M., & Neumann, P.J. (2003). Direct-to-consumer advertising and shared liability for pharmaceutical manufacturers. JAMA, 289, 477-481.
Mintzes, B., Barer, M.L., Kravitz, R.L., Bassett, K., Lexchin, J., Kazanjian, A., et al. (2003). How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary environments with and without legal DTCA. Canadian Medical Association Journal, 169, 405-412.
Mitka, M. (2003). Survey suggesting that prescription drug ads help public is met with skepticism. JAMA, 289, 827-828.
PA and NP opinions on direct-to-consumer advertising. (2002, June). Clinician News, 6, 10.
Pines, W.L. (1998). Direct-to-consumer promotion: An industry perspective. Clinical Therapeutics, 20(Suppl. C), C96-C103.
Pulcini, J., & Vampola, D. (2002). Tracking NP prescribing trends. Nurse Practitioner, 27(10), 38-43.
Rosenthal, M.B., Berndt, E.R., Donohue, J.M., Frank, R.G., & Epstein, A.M. (2002). Promotion of prescription drugs to consumers. New England Journal of Medicine, 346, 498-505.
Sherman, J.J., Fuller, S.G., & Hunter, S.G. (1999). Perceived barriers to prescriptive practices of advanced practice nurses. Journal of the American Academy of Nurse Practitioners, 11(2), 63-68.
Spurgeon, D. (1999). Doctors feel pressurised by direct-to-consumer advertising. BMJ, 319, 1321.
U.S. Food and Drug Administration. (2003). FDA releases preliminary results of physician survey DTC Rx advertisements [FDA Talk Paper]. Retrieved September 30, 2003, from http://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01189.html
Viale, P.H. (2002). Direct-to-consumer advertising of prescription medications: Implications for patients with cancer. Oncology Nursing Forum, 29, 505-511.
Viale, P.H. (2003). What NPs should know about direct-to-consumer advertising of prescription medications. Journal of the American Academy of Nurse Practitioners, 15, 297-304.
Weintraub, A. (2003, October 6). Genentech's medicine man. Business Week, 72-80.
Wright, S.K., & Neill, K.M. (2001). Factors influencing the antibiotic-prescribing decisions of nurse practitioners. Clinical Excellence for Nurse Practitioners, 5, 159-167.
Zachry, W.M., III, Dalen, J.E., & Jackson, T.R. (2003). Clinicians' responses to direct-to-consumer advertising of prescription medications. Archives of Internal Medicine, 163, 1808-1812.
Zachry, W.M., III, Shepherd, M.D., Hinich, M.J., Wilson, J.P., Brown, C.M., & Lawson, K.A. (2002). Relationship between direct-to-consumer advertising and physician diagnosing and prescribing. American Journal of Health-System Pharmacy, 59(1), 42-49.
Zoeller, J. (1999). The top 200 drugs. American Druggist, 216(2), 41-47.